KPV
Also known as: Lysine-Proline-Valine · Lys-Pro-Val · Alpha-MSH(11-13)
KPV is the C-terminal tripeptide of alpha-MSH, retaining MSH's anti-inflammatory and antimicrobial activity without the melanin-stimulating effects. Studied for inflammatory bowel disease, atopic dermatitis, and antimicrobial protocols. No FDA approval; sold in research-chem space with growing community interest.
Last reviewed · Panya.health editorial
Panya scores vendors against an 11-signal rubric. Vendors at or above 70 out of 100 are routable; below 70 are documented but get no Panya affiliate link. For prescription peptides like Mounjaro and Wegovy, Panya routes today through licensed clinicians. For research peptides like KPV, vendor scorecards land in a follow-up sprint after legal review and payment processor selection. Until then, the page surfaces commonly-mentioned vendor names so adults can do their own diligence. We do not yet earn commission on any KPV vendor.
Not medical advice. KPV is not approved for human medical use in most jurisdictions. The data below is what users do; it is not what regulators have validated. You decide your risk profile.
What it does, and how
Alpha-melanocyte-stimulating hormone (alpha-MSH) is a 13-amino-acid peptide derived from POMC processing in the pituitary. The N-terminal sequence drives melanin synthesis via MC1R binding (the mechanism behind melanotan-1 and melanotan-2). The C-terminal Lys-Pro-Val tripeptide retains MSH's other major activity: downregulation of pro-inflammatory cytokine release (TNF-alpha, IL-6, NF-kappa-B signaling) on macrophages, monocytes, and other immune cells, plus direct antimicrobial activity against Staphylococcus aureus, Candida albicans, and other pathogens. Brzoska 2008 (Endocr Rev) and Catania 2010 (Endocr Rev) reviewed the mechanism in detail. The therapeutic appeal is anti-inflammatory effect at a fraction of the molecular size of full alpha-MSH and without the melanin / tanning side-channel. Most published work is bench-science and animal models; controlled human trials are limited.
Typical practice
Subcutaneous community practice: 250 to 500 mcg per day, sometimes split into morning and evening doses, in 4 to 8 week cycles for IBD-symptom or skin-inflammation protocols. Oral KPV is sold but bioavailability is poor (the tripeptide is degraded in the gut); some users take encapsulated forms specifically for local gut-luminal effect rather than systemic absorption. Reconstitution: 5 mg vial in 5 mL bacteriostatic water for 1 mg/mL concentration; the calculator at panya.health/tools/reconstitution-calculator handles the dose math. KPV is commonly stacked with BPC-157 in gut-healing protocols; the combination is community practice, not validated.
The dosing above is community practice, not a regulator-validated protocol. Trial-validated dosing for KPV in humans does not exist for most use cases listed.
Risks and contraindications
Side effect profile in published literature is mild: occasional injection site reactions, rare reports of mild flushing. No consistent cardiovascular, hepatic, or hematologic signals in animal studies or the limited human work. The mechanism (anti-inflammatory cytokine modulation) is similar to other immunomodulatory drugs but the magnitude of effect is modest, which is part of why the molecule has been hard to push through formal trials. Anyone with active autoimmune disease under specialist care should consult their rheumatologist or gastroenterologist before adding KPV; immunomodulation interactions are real even at modest dose. Pregnancy and breastfeeding off-limits by default. Active or recent cancer worth flagging because alpha-MSH-pathway signaling is implicated in some melanoma biology, though KPV specifically does not engage MC1R.
Where this stands legally
Not FDA-approved. Not on the 503A bulks list. Sold legally as a research chemical 'not for human consumption.'
Not a controlled substance. MHRA does not regulate research peptides; sale is technically lawful but human use is medically unsupervised.
Not on EMA's approved list. Treated as a research chemical in most member states.
TGA Schedule 4 by default for unapproved peptides. Personal-use postal imports actively investigated.
Not formally scheduled. Available through Bangkok wellness clinics that offer gut-healing protocols, often bundled with BPC-157.
MOHAP treats unapproved peptides as prescription-only by default. Personal-use imports require a doctor's letter.
Where users say they source it
Names below are sourced from community discussion. None are currently scored against the Panya 11-signal rubric. Panya does not earn commission on any of these. You can search them yourself; treat the list as a starting point for your own diligence, not an endorsement.
- Pure RawzPending Panya 11-signal audit
- Limitless LifePending Panya 11-signal audit
- AminolabsPending Panya 11-signal audit
- Bangkok wellness clinics (gut-healing protocols, often paired with BPC-157)Pending Panya 11-signal audit
Full vendor scorecards for KPV land in a follow-up sprint after lawyer review and payment processor selection. We will not route users to any vendor that scores below 70 on the rubric.
Papers worth reading directly
- Brzoska et al. — Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo. Endocr Rev, 2008 →
- Catania et al. — alpha-Melanocyte-stimulating hormone in normal human physiology and disease states. Endocr Rev, 2010 →
- Cutuli et al. — Antimicrobial effects of alpha-MSH peptides. J Leukoc Biol, 2000 →
- Bettenworth et al. — The tripeptide KPV protects mice from dextran sodium sulfate-induced colitis. PLoS One, 2011 →
Panya blog posts
The phrase on every grey-market peptide site. What it actually means, what it does not mean, and why reading it wrong costs people money.
The clinic route costs more and takes longer. The research-chem route puts more on you. Neither is wrong. Here is how to choose.
Adjacent reading
Track KPV in your peptide journal.
Panya users log their full stack at panya.health/journey. Public-by-default with per-entry privacy controls. Vote-validated by the community.